Back to Search
JOHN GLASPY, MD
MD
Hematology & Oncology Physician
NPI: 1639104250IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
G42778(CA)
Education
UNIVERSITY OF CALIFORNIA, GEFFEN SCHOOL OF MEDICINE
Class of 1979
Research & Publications (20)
Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
PMID 19170225·Cancer·2009
4-observational
Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
PMID 16925109·Oncology (Williston Park)·2006
6-review
Phase III clinical trials with darbepoetin: implications for clinicians.
PMID 15792914·Best Pract Res Clin Haematol·2005
4-observational
Every-three-week erythropoietic support during chemotherapy for cancer: current status and future issues.
PMID 18632430·Support Cancer Ther·2005
8-other
Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon).
PMID 16244505·Oncology·2005
6-review
The development of erythropoietic agents in oncology.
PMID 16083329·Expert Opin Emerg Drugs·2005
6-review
Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa.
PMID 15911237·Eur J Cancer·2005
3-trial
Hematopoietic management in oncology practice. Part 2. Erythropoietic factors.
PMID 14723012·Oncology (Williston Park)·2003
6-review
Hematopoietic management in oncology practice. Part 1. Myeloid growth factors.
PMID 14682110·Oncology (Williston Park)·2003
6-review
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
PMID 12599240·Cancer·2003
3-trial
Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
PMID 12435170·Oncology (Williston Park)·2002
3-trial
Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency.
PMID 12380957·Oncology (Williston Park)·2002
6-review
The potential for anemia treatment to improve survival in cancer patients.
PMID 12380953·Oncology (Williston Park)·2002
6-review
Therapeutic options in the management of renal cell carcinoma.
PMID 12068388·Semin Oncol·2002
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 100 MEDICAL PLZ, STE 550
LOS ANGELES, CA 90095 - Phone
- (310) 794-4955
Quick Facts
- NPI
- 1639104250
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 47
- Publications
- 20
Are you this provider?
Claim Your Profile